SCHEMBL1407884

SCHEMBL1407884

COc1ccccc1CNC(=O)Nc1ccc(-c2c3cccc(C(F)(F)F)c3nn2C(F)c2cccc(F)c2F)cc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 2/20 0.44
NR1H2 P55055 3/20 0.42
NR1H3 Q13133 3/20 0.42
NR1I2 O75469 1/20 0.42
NR3C1 P04150 1/20 0.42
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.41
MAPT P10636 2/20 0.41
HTT P42858 1/20 0.41
PKM P14618 1/20 0.40
MAPK1 P28482 1/20 0.40
RAB9A P51151 1/20 0.40
ADORA3 P0DMS8 1/20 0.39
NAMPT P43490 3/20 0.39
NTRK1 P04629 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
DDX3X O00571 1/20 0.38
ANO1 Q5XXA6 1/20 0.37
C5AR1 P21730 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3857878 0.79 NR1H2 (0.53) ROCK2NR1H2NR1H3NR1I2NR3C1
SCHEMBL27730583 0.70 NR1H2 (0.47) NR1H2NR1H3NR1I2NR3C1
SCHEMBL5246499 0.68 NR1H2 (0.35) NR1H2NR1H3NR1I2NR3C1
SCHEMBL5283390 0.67 SOS1 (0.43) NR1H2NR1H3NR1I2NR3C1
SCHEMBL1414406 0.65 NR1H2 (0.50) NR1H2NR1H3NR1I2NR3C1DDX3X
SCHEMBL4637492 0.65 KMT2A (0.61) ROCK2KMT2AMEN1MAPTHTT
SCHEMBL5348609 0.64 NR1H2 (0.45) NR1H2NR1H3NR1I2NR3C1
SCHEMBL1407573 0.64 NR1H2 (0.51) NR1H2NR1H3NR1I2NR3C1NAMPT
SCHEMBL1407166 0.63 NR1H2 (0.56) NR1H2NR1H3NR1I2NR3C1MAPT
SCHEMBL29312949 0.63 ROCK2 (0.67) ROCK2KMT2AMEN1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2295429-A1 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases Wyeth LLC (US) 2011-03-16 EP disclosed